Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 3/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.41 |
| ▸ | TRPA1 | O75762 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4833445 | 0.93 | RORC (0.45) | RORCLMNATRPA1 | |
| SCHEMBL4837253 | 0.93 | RORC (0.41) | RORCMAPTCACNA1B | |
| SCHEMBL4841534 | 0.92 | LIPG (0.45) | RORCLMNAP2RX7TRPA1KMT2A | |
| SCHEMBL3827372 | 0.90 | RORC (0.46) | RORCP2RX7TRPA1KMT2AMAPT | |
| SCHEMBL4841652 | 0.90 | NPC1 (0.41) | RORCNPC1P2RX7TRPA1KMT2A | |
| SCHEMBL4842736 | 0.88 | GNRHR (0.43) | RORCLMNATRPA1MAPT | |
| SCHEMBL4844778 | 0.88 | TRPA1 (0.42) | RORCNPC1LMNATRPA1KMT2A | |
| SCHEMBL3827382 | 0.88 | TRPA1 (0.43) | RORCP2RX7TRPA1KMT2AKDM4E | |
| SCHEMBL3841683 | 0.88 | BACE1 (0.47) | RORCP2RX7TRPA1KMT2AKDM4E | |
| SCHEMBL4041379 | 0.88 | TRPA1 (0.42) | RORCP2RX7TRPA1KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7465811-B2 | Indoline compounds | LABORATOIRES FOURNIER S.A. (FR) | 2008-12-16 | — | — | US | disclosed |
| US-20080119465-A1 | Novel Indoline Compounds | LABORATORIES FOURNIER S.A. (FR) | 2008-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119465-A1 | Novel Indoline Compounds | GPR119, INSR, IRS1 | RORC 1777/4885NPC1 51/4885LMNA 1943/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.